Arrowhead Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ARWR)

$3.45 -0.15 (-4.17 %)
(As of 12/11/2017 01:51 PM ET)
Previous Close$3.60
Today's Range$3.40 - $3.59
52-Week Range$1.20 - $4.54
Volume901,000 shs
Average Volume977,022 shs
Market Capitalization$257.96 million
P/E RatioN/A
Dividend YieldN/A
Beta1.8

About Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Arrowhead Pharmaceuticals logoArrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company's preclinical pipeline of RNA interference (RNAi) therapeutics includes both subcutaneously administered liver-targeted candidates and extra-hepatic candidates. The Company's pre-clinical-stage drug candidates include ARO-HBV, ARO-AAT, ARO-LPA, ARO-AMG1, ARO-F12 and ARO-HIF2. ARO-HBV is an RNAi therapeutic candidate for the treatment of chronic hepatitis B infection. ARO-AAT is a therapeutic candidate for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency.

Receive ARWR News and Ratings via Email

Sign-up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ARWR
CUSIPN/A
Phone626-304-3400

Debt

Debt-to-Equity Ratio0.03%
Current Ratio3.84%
Quick Ratio3.84%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$160,000.00
Price / Sales1,612.23
Cash FlowN/A
Price / CashN/A
Book Value$1.56 per share
Price / Book2.21

Profitability

Trailing EPS($0.66)
Net Income$-81,720,000.00
Net Margins-201.84%
Return on Equity-46.73%
Return on Assets-34.08%

Miscellaneous

Employees94
Outstanding Shares74,770,000

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Frequently Asked Questions

What is Arrowhead Pharmaceuticals' stock symbol?

Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."

How were Arrowhead Pharmaceuticals' earnings last quarter?

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) posted its quarterly earnings data on Tuesday, August, 9th. The biotechnology company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.05. The biotechnology company had revenue of $39.58 million for the quarter, compared to the consensus estimate of $0.05 million. Arrowhead Pharmaceuticals had a negative return on equity of 46.73% and a negative net margin of 201.84%. The business's revenue for the quarter was down 68.0% compared to the same quarter last year. During the same quarter last year, the company earned ($0.27) earnings per share. View Arrowhead Pharmaceuticals' Earnings History.

When will Arrowhead Pharmaceuticals make its next earnings announcement?

Arrowhead Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, December, 12th 2017. View Earnings Estimates for Arrowhead Pharmaceuticals.

Where is Arrowhead Pharmaceuticals' stock going? Where will Arrowhead Pharmaceuticals' stock price be in 2017?

5 brokers have issued twelve-month price targets for Arrowhead Pharmaceuticals' shares. Their forecasts range from $2.00 to $5.50. On average, they expect Arrowhead Pharmaceuticals' share price to reach $3.17 in the next twelve months. View Analyst Ratings for Arrowhead Pharmaceuticals.

Who are some of Arrowhead Pharmaceuticals' key competitors?

Who are Arrowhead Pharmaceuticals' key executives?

Arrowhead Pharmaceuticals' management team includes the folowing people:

  • Douglass B. Given M.D., Ph.D., Chairman of the Board (Age 64)
  • Christopher Richard Anzalone Ph.D., President, Chief Executive Officer, Director (Age 47)
  • Kenneth Allen Myszkowski, Chief Financial Officer (Age 50)
  • Bruce D. Given M.D., Chief Operating Officer (Age 62)
  • Patrick O'Brien, General Counsel (Age 53)
  • Michael S. Perry Ph.D., Lead Independent Director (Age 57)
  • Mauro Ferrari Ph.D., Independent Director (Age 57)
  • Edward W. Frykman, Independent Director (Age 80)

Who owns Arrowhead Pharmaceuticals stock?

Arrowhead Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include NOVARTIS AG (4.44%), NOVARTIS AG (4.44%), SILENCE THERAPEUTICS PLC (3.70%), ING Groep NV (1.08%), Allianz Asset Management GmbH (0.60%) and Schwab Charles Investment Management Inc. (0.23%). Company insiders that own Arrowhead Pharmaceuticals stock include Douglas B Given and Kenneth Allen Myszkowski. View Institutional Ownership Trends for Arrowhead Pharmaceuticals.

Who bought Arrowhead Pharmaceuticals stock? Who is buying Arrowhead Pharmaceuticals stock?

Arrowhead Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including ING Groep NV, Allianz Asset Management GmbH, Dimensional Fund Advisors LP and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Arrowhead Pharmaceuticals.

How do I buy Arrowhead Pharmaceuticals stock?

Shares of Arrowhead Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Arrowhead Pharmaceuticals' stock price today?

One share of Arrowhead Pharmaceuticals stock can currently be purchased for approximately $3.45.

How big of a company is Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals has a market capitalization of $257.96 million and generates $160,000.00 in revenue each year. The biotechnology company earns $-81,720,000.00 in net income (profit) each year or ($0.66) on an earnings per share basis. Arrowhead Pharmaceuticals employs 94 workers across the globe.

How can I contact Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals' mailing address is 225 SOUTH LAKE AVENUE SUITE 1050, PASADENA CA, 91101. The biotechnology company can be reached via phone at 626-304-3400 or via email at [email protected]


MarketBeat Community Rating for Arrowhead Pharmaceuticals (ARWR)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  154 (Vote Outperform)
Underperform Votes:  112 (Vote Underperform)
Total Votes:  266
MarketBeat's community ratings are surveys of what our community members think about Arrowhead Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.402.202.002.00
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $2.70$2.00$1.80$1.80
Price Target Upside: 27.03% downside43.66% downside2.17% downside8.43% upside

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Consensus Price Target History

Price Target History for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/27/2017Piper Jaffray CompaniesUpgradeNeutral -> Overweight$5.50HighView Rating Details
9/25/2017Cantor FitzgeraldReiterated RatingHold$2.00MediumView Rating Details
9/18/2017William BlairUpgradeMarket Perform -> OutperformHighView Rating Details
9/13/2017Chardan CapitalReiterated RatingNeutralMediumView Rating Details
8/4/2017Jefferies GroupReiterated RatingHold$2.00HighView Rating Details
(Data available from 12/11/2015 forward)

Earnings

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Earnings History and Estimates Chart

Earnings by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Arrowhead Pharmaceuticals (NASDAQ ARWR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
12/12/2017($0.10)N/AView Earnings Details
8/3/2017Q3 2017($0.13)($0.07)$5.29 million$9.34 millionViewListenView Earnings Details
5/3/2017Q2 2017($0.12)($0.08)$4.19 million$8.99 millionViewListenView Earnings Details
2/6/2017Q117($0.20)($0.17)$13.24 million$4.37 millionViewListenView Earnings Details
8/9/2016Q316($0.37)($0.32)$0.05 million$39.58 millionViewN/AView Earnings Details
5/10/2016Q216($0.37)($0.35)$0.26 million$0.04 millionViewListenView Earnings Details
2/9/2016Q1($0.41)($0.32)$0.29 million$0.04 millionViewN/AView Earnings Details
12/14/2015Q415($0.39)($0.42)$0.14 million$0.04 millionViewListenView Earnings Details
8/4/2015Q315($0.38)($0.27)$0.11 million$0.12 millionViewN/AView Earnings Details
5/11/2015Q214($0.35)($0.33)$110.00 million$43.75 millionViewListenView Earnings Details
2/9/2015Q114($0.32)($0.41)$0.24 million$0.17 millionViewN/AView Earnings Details
11/25/2014Q413($0.25)($0.33)$0.04 million$0.04 millionViewN/AView Earnings Details
8/12/2014Q313($0.22)($0.22)$0.04 million$0.04 millionViewN/AView Earnings Details
5/6/2014Q2 2014($0.18)($0.31)$0.05 million$0.04 millionViewN/AView Earnings Details
2/4/2014Q4($0.18)($0.33)ViewN/AView Earnings Details
12/18/2013Q4($0.23)($0.43)ViewListenView Earnings Details
5/9/2013Q2 2013($0.41)ViewN/AView Earnings Details
2/13/2013Q1 2013($0.33)ViewN/AView Earnings Details
12/20/2012Q4 2012($0.43)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Earnings Estimates

2017 EPS Consensus Estimate: ($0.21)
2018 EPS Consensus Estimate: ($0.68)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.22$0.22$0.22
Q2 20172($0.16)($0.11)($0.14)
Q3 20173($0.15)($0.13)($0.14)
Q4 20173($0.18)($0.10)($0.15)
Q1 20181($0.11)($0.11)($0.11)
Q2 20181($0.19)($0.19)($0.19)
Q3 20181($0.19)($0.19)($0.19)
Q4 20181($0.19)($0.19)($0.19)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Arrowhead Pharmaceuticals (NASDAQ:ARWR)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Arrowhead Pharmaceuticals (NASDAQ ARWR) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.57%
Institutional Ownership Percentage: 20.20%
Insider Trades by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Institutional Ownership by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Arrowhead Pharmaceuticals (NASDAQ ARWR) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/14/2016Douglas B. GivenDirectorSell12,000$6.72$80,640.00View SEC Filing  
8/23/2016Kenneth Allen MyszkowskiCFOSell6,900$8.00$55,200.00View SEC Filing  
8/22/2016Kenneth Allen MyszkowskiCFOSell13,100$8.00$104,800.00View SEC Filing  
12/30/2015Kenneth Allen MyszkowskiCFOSell23,347$6.13$143,117.11View SEC Filing  
10/28/2015Mauro FerrariDirectorBuy400$7.62$3,048.00View SEC Filing  
10/9/2015Mauro FerrariDirectorBuy1,900$6.19$11,761.00View SEC Filing  
1/5/2015David L LewisInsiderSell15,000$8.01$120,150.00View SEC Filing  
10/15/2014Christopher Richard AnzaloneCEOBuy16,000$6.32$101,120.00View SEC Filing  
10/1/2014Charles MckenneyDirectorSell2,500$14.70$36,750.00View SEC Filing  
9/30/2014David L LewisInsiderSell15,000$15.02$225,300.00View SEC Filing  
9/26/2014Douglas B GivenDirectorSell2,000$15.24$30,480.00View SEC Filing  
6/9/2014Charles MckenneyDirectorSell22,000$14.32$315,040.00View SEC Filing  
2/12/2014Kenneth Allen MyszkowskiCFOSell16,000$18.77$300,320.00View SEC Filing  
2/7/2014Edward W FrykmanDirectorSell3,148$15.98$50,305.04View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Arrowhead Pharmaceuticals (NASDAQ ARWR) News Headlines

Source:
DateHeadline
Arrowhead Presents New Clinical Data Demonstrating a Sustained Host Response in Hepatitis B Patients Following ... - Business Wire (press release)Arrowhead Presents New Clinical Data Demonstrating a Sustained Host Response in Hepatitis B Patients Following ... - Business Wire (press release)
www.businesswire.com - December 7 at 6:56 AM
Arrowhead Pharmaceuticals to Webcast 2017 Fiscal Year End Results - Business Wire (press release)Arrowhead Pharmaceuticals to Webcast 2017 Fiscal Year End Results - Business Wire (press release)
www.businesswire.com - December 7 at 6:56 AM
ARWR: New HBV Clinical Data of ARC-520 Presented at HEP DART MeetingARWR: New HBV Clinical Data of ARC-520 Presented at HEP DART Meeting
finance.yahoo.com - December 7 at 6:56 AM
Arrowhead Pharma Wins in Midstage Hepatitis StudyArrowhead Pharma Wins in Midstage Hepatitis Study
finance.yahoo.com - December 6 at 3:20 PM
Arrowhead Presents New Clinical Data Demonstrating a Sustained Host Response in Hepatitis B Patients Following RNAi TherapyArrowhead Presents New Clinical Data Demonstrating a Sustained Host Response in Hepatitis B Patients Following RNAi Therapy
finance.yahoo.com - December 6 at 3:20 PM
Arrowhead Pharmaceuticals to Webcast 2017 Fiscal Year End ResultsArrowhead Pharmaceuticals to Webcast 2017 Fiscal Year End Results
finance.yahoo.com - December 6 at 6:59 AM
Arrowhead Pharmaceuticals (ARWR) to Release Earnings on TuesdayArrowhead Pharmaceuticals (ARWR) to Release Earnings on Tuesday
www.americanbankingnews.com - December 5 at 1:44 AM
Arrowhead Pharmaceuticals (ARWR) Rating Lowered to Hold at BidaskClubArrowhead Pharmaceuticals (ARWR) Rating Lowered to Hold at BidaskClub
www.americanbankingnews.com - December 2 at 3:22 PM
Arrowhead Pharmaceuticals (ARWR) Upgraded to "Sell" by ValuEngineArrowhead Pharmaceuticals (ARWR) Upgraded to "Sell" by ValuEngine
www.americanbankingnews.com - November 30 at 11:02 PM
ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : November 30, 2017ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : November 30, 2017
finance.yahoo.com - November 30 at 3:20 PM
Today’s Research Reports on Trending Tickers: Arrowhead Pharmaceuticals and Array BioPharma Inc.Today’s Research Reports on Trending Tickers: Arrowhead Pharmaceuticals and Array BioPharma Inc.
finance.yahoo.com - November 30 at 3:20 PM
Arrowhead Pharmaceuticals Inc (ARWR) Expected to Announce Quarterly Sales of $7.32 MillionArrowhead Pharmaceuticals Inc (ARWR) Expected to Announce Quarterly Sales of $7.32 Million
www.americanbankingnews.com - November 29 at 3:52 AM
 Analysts Anticipate Arrowhead Pharmaceuticals Inc (ARWR) to Post -$0.13 EPS Analysts Anticipate Arrowhead Pharmaceuticals Inc (ARWR) to Post -$0.13 EPS
www.americanbankingnews.com - November 27 at 9:26 PM
Piper Jaffray Companies Upgrades Arrowhead Pharmaceuticals Inc (ARWR) to "Overweight"Piper Jaffray Companies Upgrades Arrowhead Pharmaceuticals Inc (ARWR) to "Overweight"
www.americanbankingnews.com - November 27 at 6:50 PM
Benzingas Top Upgrades, Downgrades For November 27, 2017 - BenzingaBenzinga's Top Upgrades, Downgrades For November 27, 2017 - Benzinga
www.benzinga.com - November 27 at 3:17 PM
Arrowhead Pharmaceuticals, Inc. (ARWR) Receives Consensus Recommendation of "Hold" from AnalystsArrowhead Pharmaceuticals, Inc. (ARWR) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - November 27 at 6:20 AM
Arrowhead to Present at 29th Annual Piper Jaffray Healthcare Conference - Business Wire (press release)Arrowhead to Present at 29th Annual Piper Jaffray Healthcare Conference - Business Wire (press release)
www.businesswire.com - November 15 at 2:39 AM
Arrowhead to Present at 29th Annual Piper Jaffray Healthcare ConferenceArrowhead to Present at 29th Annual Piper Jaffray Healthcare Conference
finance.yahoo.com - November 14 at 4:35 PM
Arrowhead Pharmaceuticals, Inc. (ARWR) Expected to Announce Quarterly Sales of $7.32 MillionArrowhead Pharmaceuticals, Inc. (ARWR) Expected to Announce Quarterly Sales of $7.32 Million
www.americanbankingnews.com - November 11 at 10:02 AM
ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : November 3, 2017ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : November 3, 2017
finance.yahoo.com - November 3 at 4:26 PM
Arrowhead Pharmaceuticals, Inc. (ARWR) Receives Consensus Rating of "Hold" from BrokeragesArrowhead Pharmaceuticals, Inc. (ARWR) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - November 2 at 3:32 AM
Financial Comparison: Arrowhead Pharmaceuticals (ARWR) vs. Its CompetitorsFinancial Comparison: Arrowhead Pharmaceuticals (ARWR) vs. Its Competitors
www.americanbankingnews.com - October 30 at 5:26 PM
Arrowhead Pharmaceuticals Corp (ARWR) Reports Promising ... - StreetInsider.comArrowhead Pharmaceuticals Corp (ARWR) Reports Promising ... - StreetInsider.com
www.streetinsider.com - October 23 at 10:09 PM
Arrowhead Presents Promising Preclinical Data on Development of ARO-AAT for Treatment of Alpha-1 Liver Disease at Liver Meeting® 2017Arrowhead Presents Promising Preclinical Data on Development of ARO-AAT for Treatment of Alpha-1 Liver Disease at Liver Meeting® 2017
finance.yahoo.com - October 23 at 5:07 PM
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
finance.yahoo.com - October 23 at 5:07 PM
Contrasting Sarepta Therapeutics (SRPT) and Arrowhead Pharmaceuticals (ARWR)Contrasting Sarepta Therapeutics (SRPT) and Arrowhead Pharmaceuticals (ARWR)
www.americanbankingnews.com - October 21 at 4:24 AM
Arrowhead Pharmaceuticals (ARWR) & The Competition Financial SurveyArrowhead Pharmaceuticals (ARWR) & The Competition Financial Survey
www.americanbankingnews.com - October 21 at 4:24 AM
ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : October 16, 2017ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : October 16, 2017
finance.yahoo.com - October 16 at 4:52 PM
Arrowhead Pharmaceuticals to Present Preclinical Data on ARO-AAT at The Liver Meeting®Arrowhead Pharmaceuticals to Present Preclinical Data on ARO-AAT at The Liver Meeting®
finance.yahoo.com - October 10 at 5:25 PM
Arrowhead Pharmaceuticals, Inc. (ARWR) Given Average Recommendation of "Hold" by BrokeragesArrowhead Pharmaceuticals, Inc. (ARWR) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - October 8 at 4:50 AM
Arrowhead to Present at Chardan Gene Therapy ConferenceArrowhead to Present at Chardan Gene Therapy Conference
finance.yahoo.com - October 4 at 2:07 PM
ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : October 2, 2017ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : October 2, 2017
finance.yahoo.com - October 2 at 3:56 PM
Arrowhead Data Reveal Important Considerations for Future Hepatitis B TreatmentArrowhead Data Reveal Important Considerations for Future Hepatitis B Treatment
www.businesswire.com - September 27 at 7:55 PM
Arrowhead Pharmaceuticals (ARWR) "Hold" Rating Reiterated at Cantor FitzgeraldArrowhead Pharmaceuticals' (ARWR) "Hold" Rating Reiterated at Cantor Fitzgerald
www.americanbankingnews.com - September 25 at 11:38 AM
Arrowhead Pharmaceuticals, Inc. to Post Q1 2018 Earnings of ($0.11) Per Share, William Blair Forecasts (ARWR)Arrowhead Pharmaceuticals, Inc. to Post Q1 2018 Earnings of ($0.11) Per Share, William Blair Forecasts (ARWR)
www.americanbankingnews.com - September 20 at 9:22 AM
Arrowhead Pharmaceuticals, Inc. (ARWR) Lifted to Outperform at William BlairArrowhead Pharmaceuticals, Inc. (ARWR) Lifted to Outperform at William Blair
www.americanbankingnews.com - September 18 at 11:32 PM
Analyzing Arrowhead Pharmaceuticals (ARWR) and BioCryst Pharmaceuticals (BCRX)Analyzing Arrowhead Pharmaceuticals (ARWR) and BioCryst Pharmaceuticals (BCRX)
www.americanbankingnews.com - September 17 at 2:31 AM
Arrowhead Pharmaceuticals, Inc. (ARWR) Receives "Neutral" Rating from Chardan CapitalArrowhead Pharmaceuticals, Inc. (ARWR) Receives "Neutral" Rating from Chardan Capital
www.americanbankingnews.com - September 16 at 7:18 AM
Here's What Caused Arrowhead Pharmaceuticals' Stock to Spike TodayHere's What Caused Arrowhead Pharmaceuticals' Stock to Spike Today
finance.yahoo.com - September 15 at 4:23 PM
Cantor Fitzgerald Reaffirms Hold Rating for Arrowhead Pharmaceuticals, Inc. (ARWR)Cantor Fitzgerald Reaffirms Hold Rating for Arrowhead Pharmaceuticals, Inc. (ARWR)
www.americanbankingnews.com - September 15 at 7:28 AM
Arrowhead Hosts Investor & Analyst R&D Day to Introduce TRiM™ Platform and Lead RNAi-based Drug CandidatesArrowhead Hosts Investor & Analyst R&D Day to Introduce TRiM™ Platform and Lead RNAi-based Drug Candidates
finance.yahoo.com - September 14 at 4:38 PM
Arrowhead Pharmaceuticals, Inc. (ARWR) Given Average Recommendation of "Hold" by AnalystsArrowhead Pharmaceuticals, Inc. (ARWR) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - September 13 at 5:06 AM
ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : September 12, 2017ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : September 12, 2017
finance.yahoo.com - September 12 at 2:00 AM
Arrowhead to Present at the 2017 Cantor Fitzgerald Global Healthcare ConferenceArrowhead to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 11 at 8:58 PM
Arrowhead Pharmaceuticals, Inc. :ARWR-US: Earnings Analysis: Q3, 2017 By the Numbers : September 8, 2017Arrowhead Pharmaceuticals, Inc. :ARWR-US: Earnings Analysis: Q3, 2017 By the Numbers : September 8, 2017
finance.yahoo.com - September 8 at 10:05 PM
Arrowhead Pharmaceuticals to Host R&D Day on RNAi-Based Therapies - Business Wire (press release)Arrowhead Pharmaceuticals to Host R&D Day on RNAi-Based Therapies - Business Wire (press release)
www.businesswire.com - September 1 at 9:40 PM
Arrowhead Pharmaceuticals to Host R&D Day on RNAi-Based TherapiesArrowhead Pharmaceuticals to Host R&D Day on RNAi-Based Therapies
finance.yahoo.com - September 1 at 4:37 PM
FY2017 EPS Estimates for Arrowhead Pharmaceuticals, Inc. Lifted by Analyst (ARWR)FY2017 EPS Estimates for Arrowhead Pharmaceuticals, Inc. Lifted by Analyst (ARWR)
www.americanbankingnews.com - August 28 at 3:38 AM
$7.32 Million in Sales Expected for Arrowhead Pharmaceuticals, Inc. (ARWR) This Quarter$7.32 Million in Sales Expected for Arrowhead Pharmaceuticals, Inc. (ARWR) This Quarter
www.americanbankingnews.com - August 27 at 5:50 AM
Contrasting Arrowhead Pharmaceuticals (ARWR) and Biopharmx Corp (BPMX)Contrasting Arrowhead Pharmaceuticals (ARWR) and Biopharmx Corp (BPMX)
www.americanbankingnews.com - August 19 at 8:44 AM

SEC Filings

Arrowhead Pharmaceuticals (NASDAQ:ARWR) SEC Filings

DateFilerForm TypeView
12/08/2017
4:21 PM
Arrowhead Pharmaceuticals (Subject)
Silence Therapeutics plc (Filed by)
Form SC 13D/A
View Filing
12/01/2017
4:02 PM
Arrowhead Pharmaceuticals (Subject)
Silence Therapeutics plc (Filed by)
Form SC 13D
View Filing

Social Media

Financials

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Arrowhead Pharmaceuticals (NASDAQ ARWR) Stock Chart for Monday, December, 11, 2017

Loading chart…

This page was last updated on 12/11/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.